Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,325 Average Price Target from Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 2,325 ($31.13).

Several research firms have recently weighed in on HIK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.82) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Berenberg Bank raised shares of Hikma Pharmaceuticals to a “buy” rating and upped their price objective for the company from GBX 2,100 ($28.12) to GBX 2,400 ($32.14) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Price Performance

Shares of LON HIK opened at GBX 1,896 ($25.39) on Thursday. The company has a market capitalization of £4.21 billion, a PE ratio of 2,962.50, a PEG ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The stock’s 50 day moving average price is GBX 1,945.79 and its 200-day moving average price is GBX 1,917.35. Hikma Pharmaceuticals has a twelve month low of GBX 1,711 ($22.91) and a twelve month high of GBX 2,165 ($28.99).

Hikma Pharmaceuticals Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s payout ratio is 9,687.50%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.